Assessment of Knowledge and Practice of Healthcare Providers in Saudi Arabia Regarding Clostridioides difficile Infection Diagnosis and Management: A Cross-Sectional Questionnaire-Based Study
Masaad Almutairi,Faris Alnezary,Rasil Alsuwaylim,Ibrahim Alsulaymi,Omar Almohammed,Abrar Thabit
DOI: https://doi.org/10.2147/idr.s450281
2024-02-15
Infection and Drug Resistance
Abstract:Masaad Saeed Almutairi, 1 Faris S Alnezary, 2 Rasil O Alsuwaylim, 1 Ibrahim Alsulaymi, 1 Omar A Almohammed, 3, 4 Abrar K Thabit 5 1 Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia; 2 Department of Pharmacy Practice, College of Pharmacy, Taibah University, Madinah, Saudi Arabia; 3 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 4 Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 5 Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia Correspondence: Masaad Saeed Almutairi, Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, 51452, Saudi Arabia, Tel +966557523133, Email Introduction: Diagnosis of Clostridioides difficile infection (CDI) depends on clinical presentation and laboratory testing. Stool diagnostic tests are essential for effective detection of toxigenic C. difficile strains. No study to date has evaluated the readability of microbiology labs in Saudi Arabia to test for CDI and evaluated the knowledge and practice of healthcare providers regarding CDI management. Therefore, this study aimed to assess the knowledge and practice of healthcare providers in Saudi Arabia regarding CDI diagnosis and treatment. Methods: A cross-sectional, descriptive, questionnaire-based study was conducted on healthcare providers in Saudi Arabia, primarily physicians and clinical pharmacists. The questionnaire was developed based on a literature review and input from infectious diseases experts. The questionnaire was administered online. Data were analyzed using descriptive and inferential statistics. Results: Of 183 respondents, 27.9% had adequate knowledge on CDI diagnosis and management. The majority were internal medicine specialists (37.7%) working in governmental or semi-governmental hospitals (80.9%) in central (46.6%) or southern (30.1%) regions of Saudi Arabia. Most participants assessed laxative use (86.3%) and reported positive C. difficile specimens to infection control (67.2%). However, knowledge varied, with 57.4% supporting unnecessary retesting and 53% assuming positive PCR test indicates moderate CDI probability. Factors such as specialization, hospital accreditation status, and bed capacity influenced knowledge levels (p< 0.01 for all factors). Conclusion: The study revealed a significant knowledge gap among Saudi healthcare providers regarding CDI diagnosis, management, and severity classification, highlighting the need for improved education and adherence to guidelines to improve patient outcomes and reduce recurrence risks. Keywords: Clostridioides difficile , Clostridium difficile , diagnosis, polymerase chain reaction, knowledge, Saudi Arabia Clostridioides difficile infection (CDI) is caused by the toxigenicity of C. difficile , an anaerobic gram-positive bacterium. The spore-forming ability of C. difficile enables it to survive in unfavorable conditions, thus contributing to its dissemination and transmission in healthcare settings and occasionally in the community. 1 Patients with CDI often have a history of recent antibiotic use, hospitalization, chronic diseases, or previous CDI episodes. Antibiotic treatment within the preceding 60 days, especially with third generation cephalosporins, penicillins with beta-lactamase inhibitors, chronic liver or kidney disease, malnutrition, and prior CDI are associated with an elevated risk of CDI. 2 In a study conducted among hospitalized patients with inflammatory bowel disease, CDI was frequently associated with active inflammatory bowel disease. Furthermore, the prior intake of nonsteroidal anti-inflammatory medications was identified as a risk factor for CDI among these patients. 3 The diagnosis of CDI is based on clinical signs and symptoms such as new onset diarrhea (≥3 loose stools in 24 hours), fever, abdominal pain, or leukocytosis. 4 Moreover, CDI diagnosis can be determined by laboratory stool diagnostic tests. A polymerase chain reaction (PCR) or a multistep algorithm is recommended to effectively detect toxigenic C. difficile strains to facilitate the diagnosis of symptomatic CDI and minimize over-diagnosis of asymptomatic carriers. 5 The Infectious Disease Society of America (IDSA) recommend using either PCR or a multistep algorithm, either glutamate dehydrogenase (GDH) and toxin, GDH and toxin then arbitrated by NAAT, or NAAT and toxin. 6 Between 2009–2011, reported CDI incidence was 50 -Abstract Truncated-
pharmacology & pharmacy,infectious diseases